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Introduction
A hallmark of cancer is evasion of apoptosis (Hanahan and 
Weinberg, 2000), which links cancer genetics and cytotoxic 
chemotherapies inextricably together (Johnstone et al., 2002). 
Apoptosis induced by chemotherapeutic agents has been attrib-
uted to the induction of DNA damage. One of the key molecules 
involved in response to DNA damage is the tumor suppressor 
protein p53 (Lakin and Jackson, 1999; Vousden and Lu, 2002). 
The loss of p53 response is thought to promote genomic insta-
bility (Yin et al., 1992) that can lead to increased resistance to 
chemotherapeutic agents. In normal unstressed cells, the p53 
protein is present at very low levels because of continuous degra-
dation mediated by Mdm2, a protein that is also transcriptionally 
activated by p53 (Wu et al., 1993). Thus, p53 and Mdm2 are 
linked to each other through an autoregulatory negative feed-
back loop (Prives, 1998). Disruption of the p53–Mdm2 complex 
is the pivotal event in p53 activation after DNA damage (Prives, 
1998; Lakin and Jackson, 1999; Vousden and Lu, 2002). In ad-
dition, recent papers have suggested that enhanced translation 
of p53 mRNA is also an important step in the induction of p53 
in stressed cells (Giaccia and Kastan, 1998; Mazan-Mamczarz 
et al., 2003; Takagi et al., 2005), although the mechanisms 
remain largely unknown.
Translation of eukaryotic mRNAs is predominantly regu-
lated at the level of initiation (Gray and Wickens, 1998; Raught 
et al., 2000; Dever, 2002), when the ribosome is recruited to the 
mRNA. The eukaryotic translation initiation factor (eIF) com-
plex eIF4F is required for this multistep process and is com-
posed of the cap-binding protein eIF4E; the RNA helicase 
eIF4A; and the scaffold protein eIF4G, which provides binding 
sites for eIF4E, eIF4A, and the poly(A)-binding protein (PABP; 
Gray and Wickens, 1998; Raught et al., 2000; Dever, 2002). 
eIF4A is required to unwind the second structure in the 5′ un-
translated region (UTR). The helicase activity of eIF4F should 
be proportional to the amount of the secondary structure in the 
5′ UTR, which would otherwise affect translational effi  ciency 
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IGF-1R activity reduces translational synthesis of p53 and 
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protein stability by reducing p53 ubiquitination and main-
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induced p53 is therefore reduced in Igf-1r
−/− mouse 
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reduces p53 and Mdm2 translation through a gene-
  speciﬁ  c mechanism mediated by the respective 5′ un-
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involved in this translational inhibition. These results dem-
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(Gray and Wickens, 1998; Raught et al., 2000). The effi  ciency 
of translation initiation is tightly coupled with cell cycle pro-
gression and cell growth, with translational induction occurring 
in response to mitogenic stimulation (Raught et al., 2000; Dever, 
2002). Such changes in translation are normally mediated by 
alterations in the expression or phosphorylation status of the 
various translation initiation factors involved (Gray and Wickens, 
1998; Raught et al., 2000; Dever, 2002). Hypophosphorylated 
eIF4E–binding protein 1 (BP1) competes with eIF4G for bind-
ing to eIF4E and prevents formation of the eIF4F complex 
(Gray and Wickens, 1998; Raught et al., 2000; Dever, 2002). In 
addition, the interaction of eIF4E with its partners can be regu-
lated by the availability of free eIF4G, which may be regulated 
at the levels of synthesis and turnover (Morley et al., 1997). Despite 
suggestions that the control of translation may be regulated by 
growth-factor signaling (Dever, 2002; Rajasekhar et al., 2003), 
the relative contribution of translational effects of these signal-
ing pathways in their corresponding cellular activities and the 
mechanisms involved have remained unclear.
Insulin-like growth factor 1 receptor (IGF-1R) is a mem-
brane-associated tyrosine kinase receptor that plays an impor-
tant role in cell growth, transformation, and protection of cells 
from a variety of apoptotic stimuli (LeRoith and Roberts, 2003; 
Pollak et al., 2004; Samani et al., 2007). IGF-1R signaling pro-
tects cells from apoptosis mainly through the phosphoinositide-3 
kinase (PI-3K)–Akt and Ras–Raf–MAPK pathways (Párrizas 
et al., 1997; Gooch et al., 1999; Peruzzi et al., 1999). Inhibition 
of IGF-1R has been shown to block tumor growth and sensitize 
cells to antitumor treatments (Samani et al., 2007), indicating that 
IGF-1R is a promising target for cancer therapeutics (De Meyts 
and Whittaker, 2002). In other situations, however, IGF-1R sig-
naling contributes to cell death (Kooijman, 2006). Overexpres-
sion of the C terminus of the IGF-1R β subunit induced apoptosis 
in culture cells (Hongo et al., 1998; Liu et al., 1998), suggesting 
that IGF-1R has intrinsic proapoptotic features. Remarkably, a 
potential role of IGF-1R in mediating cell death in vivo was 
suggested by the fi  ndings that Igf-1r
+/– mice exhibited enhanced 
resistance to oxidative damage compared with wild-type mice 
(Holzenberger et al., 2003). Furthermore, it has been reported 
that IGF-1R signaling may be able to potentiate p53 induction 
(Wang et al., 1998; Macaulay et al., 2001), which can induce 
apoptosis. Although the antiapoptotic functions of IGF-1R have 
been well established (Pollak et al., 2004; Samani et al., 2007), 
the mechanism by which IGF-1R sends a proapoptotic signal is 
not well known. A better understanding of the proapoptotic func-
tion of IGF-1R may reveal more rational approaches for cancer 
therapies targeting IGF-1R signaling.
In this paper, we have used Igf-1r
–/– mouse embryonic 
fi  broblasts (MEFs) and a specifi  c IGF-1R inhibitor, AG1024, to 
decipher the role of IGF-1R in regulating cellular apoptosis in-
duced by the chemotherapeutic agent etoposide and the mecha-
nisms involved. We found that inhibition of IGF-1R reduces 
DNA-damage–induced apoptosis through translational inhibi-
tion of p53 and Mdm2 expression. Our results not only provide 
insights into the role for IGF-1R in the p53-induced apoptotic 
response but also reveal a critical role for translational regula-
tion of the p53–Mdm2 feedback loop by IGF-1R signaling.
Results
Attenuation of etoposide-induced apoptosis 
and p53 induction in MEFs lacking Igf-1r
We observed that R
− MEFs, in which the Igf-1r gene has been 
knocked out (Miura et al., 1995), were insensitive to apoptosis 
induced by the DNA-damage agent etoposide compared with 
R
+ MEFs (Fig. 1 A; see Materials and methods). Detection of the 
cleavage of apoptotic markers caspase-3 and poly (ADP-ribose) 
polymerase (PARP) supported this observation (Fig. 1 B). Addition-
ally, treatment with the IGF-1R kinase inhibitor AG1024, which 
suppressed both the autophosphorylation activity of IGF-1R 
and its downstream signaling (Fig. 1 D), reduced apoptosis 
in response to etoposide in R
+ MEFs (Fig. 1 C). Furthermore, 
transient expression of plasmids encoding the wild-type IGF-1R 
(IGF-1R-WT) but not the kinase-inactive IGF-1R (IGF-1R-YF) 
in R
− MEFs resulted in an increased apoptotic response to 
etoposide (Fig. 1 E). Collectively, these results suggest that fun-
ctional IGF-1R renders MEFs more susceptible to etoposide-
induced apoptosis.
Because p53 is a key mediator of apoptosis induced by 
DNA damage (Vousden and Lu, 2002), we examined whether 
apoptosis of MEFs induced by etoposide depended on func-
tional p53. Both R
+ and R
− MEFs transfected with dominant-
negative p53 (GFP-p53DD) exhibited a reduced apoptotic 
response to etoposide (Fig. 2 A), indicating that p53 is required 
for the apoptotic response of MEFs to etoposide. Given that p53 
transcriptional activity is required for p53-dependent apoptosis 
after DNA damage (Chao et al., 2000), we next investigated 
whether IGF-1R inhibition could impair p53 activation. To this 
end, we performed luciferase assays using p53-reponsive ele-
ments (p53bs-luc) and unstimulated elements (p53ms-luc). The 
p53bs-luc reporter had higher relative luciferase activity in R
+ 
than in R
− MEFs after DNA damage (Fig. 2 B), implying that 
DNA-damage–induced p53 activation is impaired in R
− MEFs.
Because p53 activation after DNA damage is associated at 
least in part with p53 accumulation (Lakin and Jackson, 1999), 
we next analyzed the induction of p53 protein levels in R
+ and 
R
− MEFs. Titration experiments revealed a substantial increase 
in the amount of p53 protein as well as its downstream targets 
p21 and Mdm2 in response to etoposide in R
+ compared with 
R
− MEFs (Fig. 2 C). Furthermore, AG1024 attenuated p53 in-
duction followed by etoposide treatment in R
+ but not in R
− 
MEFs (Fig. 2 D), suggesting that IGF-1R–mediated sensitiza-
tion of MEFs to p53 accumulation was dependent on IGF-1R 
kinase activity. In agreement with p53 expression, p21 and Mdm2 
induction in response to etoposide treatment was also impaired 
in R
+ but not in R
− MEFs after AG1024 treatment (Fig. 2 D). To 
test the generality of our observations, we next examined whether 
the lack of IGF-1R could reduce p53 induction in response to 
other anticancer agents, such as doxorubicin and Taxol. We found 
that in R
− MEFs, the induction of p53 and p21 in response to 
doxorubicin or Taxol was impaired (Fig. S1 A, available at 
http://www.jcb.org/cgi/content/full/jcb.200703044/DC1). How-
ever, despite impaired p53 induction, R
− MEFs exhibited en-
hanced apoptotic responses to doxorubicin and Taxol (Fig. 
S1 B), suggesting that impaired p53 induction in R
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not always translate into reduced apoptosis. Because p53 induc-
tion may also result in G1 cell cycle arrest in response to DNA 
damage (Lukas et al., 2004), we next examined the cell cycle 
profi  les of R
+ and R
− MEFs after DNA damage. Treatment with 
etoposide induced cell cycle arrest at the G1/S and G2/M check-
points in R
+ MEFs, whereas R
− MEFs exhibited a reduced G1 
Figure 1.  Requirement of IGF-1R for etoposide-induced apoptosis in MEFs. (A) Dose-dependent etoposide-induced apoptosis in MEFs. R
+ and R
− MEFs 
were subjected to different doses of etoposide for 60 h, and apoptosis was analyzed by ﬂ  ow cytometry. Values are mean ± SD from three independent ex-
periments. (B) Etoposide-induced cleavage of caspase-3 and PARP in MEFs. Cells were treated with etoposide at 2 μM for the indicated times. Whole cell 
extracts were prepared and subjected to Western blot analysis with the indicated antibodies. Actin was used as a loading control. (C) Reduction of etoposide-
induced apoptosis in R
+ MEFs by AG1024 treatment. R
+ and R
− MEFs were pretreated with or without 20 μM AG1024 for 18 h and then subjected to 
etoposide for 48 h. Three independent experiments were performed (mean ± SD; *, P < 0.01). (D) Inhibitor speciﬁ  city. R
+ and R
− MEFs were treated with 
AG1024 as indicated for 18 h. Cell lysates were probed with the indicated antibodies for phosphorylation of endogeneous proteins. (E) Reconstitution with 
functional IGF-1R sensitizes R
− MEFs to apoptosis. R
− MEFs were transiently cotransfected with either an empty vector, IGF-1R-WT, or IGF-1R-YF and a plas-
mid encoding EGFP, and then treated with etoposide for 48 h. The percentage of apoptotic cells was determined by ﬂ  ow cytometry as the fraction of GFP-
positive cells with sub-G1 DNA content (left; mean ± SD; *, P < 0.05). The expression and activity of IGF-1R-WT and IGF-1RYF were conﬁ  rmed using the 
indicated antibodies (right).JCB • VOLUME 178 • NUMBER 6 • 2007  998
arrest (Fig. S1 C), which is consistent with the impaired p53 
induction observed in R
− MEFs.
To determine whether IGF-1R inhibition could impair p53 
accumulation and apoptosis in human tumor cells, we treated 
human hepatocellular carcinoma SK-hep1 and human colon 
cancer HCT116 cells with AG1024. Treatment of these cells 
with AG1024 impaired p53 accumulation as well as apop-
tosis in response to etoposide (Fig. S2, A and B, available at 
http://www.jcb.org/cgi/content/full/jcb.200703044/DC1). Notably, 
AG1024-treated and -untreated p53
–/– cells showed a similar 
level of apoptosis in response to etoposide (Fig. S2 B), indicat-
ing that IGF-1R inactivation cannot protect these cells against 
Figure 2.  Requirement of IGF-1R for p53 accumulation and activation in response to etoposide in MEFs. (A) Etoposide-mediated apoptosis is reduced in 
MEFs upon transfection with GFP-p53DD. R
+ and R
− MEFs were transfected with either an empty vector or GFP-p53DD and treated with etoposide for 48 h. 
Apoptotic cell death was measured as described in Fig. 1 E. Values are mean ± SD from three independent experiments. *, P < 0.05; **, P < 0.01. 
The expression and activity of GFP-p53DD were determined using antibodies against GFP and p21. (B) Detection of p53 activation in MEFs. R
+ and R
− 
MEFs were cotransfected with p53bs-luc (wild-type responsive elements) or p53ms-luc (mutant responsive elements) and a plasmid expressing renilla that 
served as an internal control. After etoposide treatments, luciferase activity was measured. Relative luciferase activity is expressed as light units normalized 
for renilla luciferase activity. Data shown are from one out of three independent experiments with comparable results (mean ± SD). (C) Induction of p53 
and its downstream targets Mdm2 and p21 after etoposide treatment in R
+ and R
− MEFs. R
+ and R
− MEFs were treated with the indicated doses of etopo-
side for 12 h, and whole cell lysates were analyzed by Western blot analysis with the indicated antibodies. (D) AG1024 treatment impairs etoposide-
induced p53 induction and activation in R
+ but not R
− MEFs. R
+ and R
− MEFs were pretreated with AG1024 before etoposide treatment. Whole cell lysates 
were harvested and subjected to Western blot analysis with the indicated antibodies. (E) Dose course of apoptosis induced by ionomycin in R
+ and R
− MEFs. 
MEFs were subjected to different doses of ionomycin and collected after 36 h, and apoptosis was analyzed by ﬂ  ow cytometry. Values are mean ± SD from 
three independent experiments.TRANSLATIONAL REGULATION OF P53 FUNCTION BY IGF-1R • XIONG ET AL. 999
DNA-damage–induced apoptosis in the absence of p53. In 
addition, we tested whether IGF-1R inhibition could protect 
cells from p53-independent apoptotic stimuli such as ionomy-
cin, which causes calcium fl  ux. Fig. 2 E demonstrates that the 
ability of ionomycin to induce apoptosis was unaffected in R
− 
MEFs. Similarly, ionomycin induced comparable levels of 
p53-independent cell death in both untreated and AG1024-
treated HCT116 cells (Fig. S2 C). Thus inactivation of IGF-1R 
antagonizes the ability of etoposide to increase p53 abundance 
and activity and thereby impairs p53-dependent functions in-
cluding apoptosis and cell cycle arrest.
Enhancement of p53 protein stability 
in Igf-1r
−/− MEFs
To defi  ne the mechanisms that underlie attenuated p53 response 
to etoposide in R
− MEFs, we next investigated the integrity of 
DNA-damage checkpoint pathways in R
− MEFs. Phosphoryla-
tion of p53 on ser18 (corresponding to serine 15 in human p53) 
contributes to p53 activation after DNA damage through in-
creased binding to the p300 coactivator protein (Dumaz and 
Meek, 1999). We found that etoposide treatment induced simi-
lar levels of ser18 phosphorylation of p53 in both R
+ and R
− 
MEFs (unpublished data). In addition, the experiment to detect 
p53 localization revealed that the etoposide-induced p53 pro-
tein in both R
+ and R
− MEFs was localized in the nuclei (un-
published data), again indicating that inactivation of IGF-1R 
impairs p53 induction without affecting the DNA-damage sig-
naling to p53.
Because DNA damage increases p53 protein levels mainly 
by up-regulating p53 protein stability (Prives, 1998; Lakin and 
Jackson, 1999), we reasoned that IGF-1R inhibition might regu-
late p53 accumulation in response to DNA damage by infl  uenc-
ing p53 protein stability. Indeed, treatment of R
+ MEFs with 
etoposide increased p53 stability (Fig. 3, A and B). Importantly, 
there was no measurable difference in p53 stability in etopo-
side-treated R
+ and R
− MEFs (Fig. 3 A). Likewise, p53 protein 
was stable in untreated and AG1024-treated SK-hep1 cells after 
etoposide treatment (Fig. S3, A and B, available at http://www
.jcb.org/cgi/content/full/jcb.200703044/DC1). Surprisingly, we 
detected a higher stability of p53 protein in untreated R
− MEFs 
than in untreated R
+ MEFs (Fig. 3 B). Similarly, the IGF-1R in-
hibitor also stabilized p53 protein in SK-hep1 cells (Fig. S3 B). 
To confi  rm that a lack of IGF-1R activity can stabilize p53 pro-
tein, R
+ and R
− MEFs were pulse labeled with [
35S]methionine/
Figure 3.  IGF-1R inhibition increases p53 protein stability. (A) Measurement of p53 protein stability in etoposide-treated MEFs. R
+ and R
− MEFs were 
treated with etoposide for 24 h before exposure to CHX. Extracts prepared at the indicated times after the addition of CHX were analyzed by Western blot 
analysis (top). The stability of p53 protein was quantiﬁ  ed by ImageQuant software (bottom). p53 band density was normalized to actin density, and then 
expressed relative to the t = 0 controls and plotted on a semilogarithmic scale by a linear regression program against the times of CHX treatments. Each 
decreased unit of log2 (band density) is equivalent to one half life. (B) Measurement of the p53 protein stability in unstressed MEFs. R
+ and R
− MEFs were 
treated with CHX for the indicated times. Quantitation of the stability of p53 protein was performed as described in A. Values are mean ± SD from three in-
dependent experiments. (C) Lack of IGF-1R leads to enhanced p53 protein stability. MEFs were pulse labeled with [
35S]methionine/cysteine and chased as 
described in Materials and methods. p53 protein was immunoprecipitated and resolved by SDS-PAGE (left) and the amount of 
35S was quantiﬁ  ed by Phos-
phorImaging (right). (D) Conjugation of ubiquitin to p53 protein is reduced upon IGF-1R loss. R
+ and R
− MEFs were harvested for immunoprecipitation. 
Equal amounts of immunoprecipitated p53 proteins were subjected to Western blot analysis with antibodies against ubiquitin.JCB • VOLUME 178 • NUMBER 6 • 2007  1000
cysteine followed by a 4-h chase. The results showed that the 
half-life of p53 protein was  15 and 60 min in R
+ and R
− 
MEFs, respectively (Fig. 3 C), again demonstrating an increased 
half-life of p53 protein upon IGF-1R inhibition.
Because the degradation of p53 is mediated by the ubiq-
uitin–proteasome pathway, we next examined the amount of ubiq-
uitin that is conjugated to p53 for degradation. The results showed 
a remarkable decrease in p53–ubiquitin complexes in R
− MEFs 
and AG1024-treated SK-hep1 cells (Fig. 3 D and Fig. S3 C), 
implying that IGF-1R inhibition may increase p53 stability by 
reducing p53 ubiquitination.
Reduction of mdm2 and p53 mRNA 
translation by IGF-1R inhibition
Because the ubiquitin ligase Mdm2 is a key regulator of p53 
protein turnover (Prives, 1998), we tested whether Mdm2 was 
involved in the regulation of p53 stability by IGF-1R inhibition. 
R
− MEFs as well as AG1024-treated Sk-hep1 cells expressed 
lower levels of Mdm2 protein compared with R
+ MEFs and un-
treated Sk-hep1 cells, respectively (Fig. 4 A and Fig. S3 D). 
Furthermore, AG1024 treatment led to the down-regulation of 
Mdm2 protein in wild-type HCT116 cells and HCT116 p53
–/– 
cells (Fig. 4 B), implying that Mdm2 expression is down-regulated 
in a p53-independent manner in response to IGF-1R inhibition. 
RT-PCR analysis revealed no detectable difference in mdm2 
mRNA levels in HCT116 p53
+/+ and p53
–/– cells upon IGF-1R 
inhibition (Fig. 4 C), suggesting a translational or posttransla-
tional role of IGF-1R signaling in regulating Mdm2 expression. 
We therefore examined Mdm2 protein synthesis by metabolic 
labeling assay. The 
35S-labeling experiments revealed a reduced 
synthesis of 
35S-labeled Mdm2 in either p53
+/+ or p53
–/– HCT116 
cells upon AG1024 treatment (Fig. 4 D). The reduction in 
35S 
incorporation was not caused by the reduced stabilization of 
Mdm2 because treatment of HCT116 p53
+/+ cells with AG1024 
did not alter the half-life of Mdm2 protein (Fig. 4, E and F). In 
fact, using a 
35S-pulse label analysis, we demonstrated that the 
half-life of Mdm2 protein in untreated and AG1024-treated 
HCT116 p53
+/+ cells was  55 and 60 min, respectively (Fig. 4 F). 
Thus, these results suggest that inhibition of IGF-1R activity 
decreases the translational rate of mdm2 transcripts and con-
sequently the expression levels of Mdm2 protein, therefore 
increasing p53 protein stability.
It should be noted that IGF-1R inhibition did not up-
  regulate the steady-state levels of p53 protein in either of the 
examined MEFs or tumor cells (Figs. 2 D and 4 B, and see Fig. 
7 A), although degradation of p53 protein had been severely 
attenuated. It is therefore conceivable that, despite decreased p53 
turnover, IGF-1R inhibition might maintain low levels of p53 
Figure 4.  IGF-1R inhibition down-regulates Mdm2 
expression at the translational level. (A) Measurement 
of Mdm2 expression in MEFs. Cell lysates were har-
vested and subjected to Western blot analysis with the 
indicated antibodies. (B) Down-regulation of Mdm2 
by IGF-1R inhibition is independent of p53. p53
+/+ 
and p53
–/– HCT116 cells were incubated with or 
without AG1024. Expression of Mdm2 protein was 
determined by immunoblotting with the indicated 
antibodies. (C) Measurement of mdm2 mRNA levels 
upon AG1024 treatment. After AG1024 treatment, 
total cellular RNA was prepared and levels of mdm2 
transcripts were revealed by semiquantitative RT-PCR. 
(D) IGF-1R inhibition reduces translation of mdm2 
mRNA in a p53-independent manner. After AG1024 
treatments, HCT116 p53
+/+ and p53
–/– cells were 
pulse labeled and newly synthesized. Mdm2 was 
immunoprecipitated from cells and analyzed by Phos-
phorImaging (top). Analysis of total cellular proteins by 
SDS-PAGE showed equal amounts of loading (bottom). 
(E) AG1024 treatment does not affect Mdm2 protein 
stability. HCT116 p53
+/+ cells were treated as described 
in C, and then exposed to CHX for the indicated times. 
Quantitative analysis of Mdm2 stability was performed 
as described in Fig. 3 A. Values are mean ± SD from 
three independent experiements. (F) HCT116 p53
+/+ 
cells were pulse labeled and chased for the indicated 
periods of time, followed by immunoprecipitation. The 
amount of 
35S was quantiﬁ  ed by PhosphorImaging.TRANSLATIONAL REGULATION OF P53 FUNCTION BY IGF-1R • XIONG ET AL. 1001
protein by reducing p53 synthesis. Northern blot analysis re-
vealed similar levels of p53 mRNA in R
+ and R
− MEFs (Fig. 
5 A); therefore, we reasoned that IGF-1R inhibition might counter-
balance the effects of the enhancement of p53 protein stability 
by reducing p53 synthesis at the translational level. We did 
observe a reduction in [
35S]methionine/cysteine–labeled p53 in 
R
− MEFs (Fig. 5 B). Similarly, treatment of SK-hep1 cells with 
IGF-1R inhibitor also decreased synthesis of 
35S-labeled p53 
(Fig. S4 B, available at http://www.jcb.org/cgi/content/full/jcb
.200703044/DC1), whereas p53 mRNA levels remained constant 
(Fig. S4 A). Collectively, these results suggest that decreased 
p53 mRNA translation may neutralize reduced p53 degradation 
in response to IGF-1R inhibition. Thus, our analyses indicate 
that R
− MEFs and AG1024-treated cells are refractory to p53 
induction after DNA damage because of the prolonged half-life 
of p53 and reduced p53 synthesis.
Disruption of translation initiation complex 
and gene-selective impairment in translation 
efﬁ  ciency by IGF-1R inhibition
The observation that protein synthesis of Mdm2 and p53 pro-
teins is reduced after IGF-1R inhibition suggests a possible role 
for IGF-1R in translational regulation of gene expression. It has 
been reported that growth-factor signaling could regulate 
mRNA translation by modulating the general translation initia-
tion factors (Rajasekhar et al., 2003; Kelleher et al., 2004). We 
therefore tested whether the lack of IGF-1R activity altered 
overall protein synthesis and activity of the eIF4F complex. 
Compared with R
+ MEFs, R
− MEFs had a slower rate of incor-
porating amino acids into protein (Fig. 6 A). Similar levels of 
inhibition were obtained in SK-hep1 cells with the administration 
of AG1024 (Fig. S4 C). Furthermore, IGF-1R inhibition had no 
measurable effect on the levels of eIF4A, PABP, and eIF4E pro-
teins, but resulted in a reduction in eIF4G abundance (Fig. 6 B, 
bottom). In addition, the hyperphosphorylated form of eIF4E–
BP1 was also reduced upon IGF-1R loss (Fig. 6 B, bottom). To 
determine whether these modulations could disrupt the eIF4F 
complex, we next examined the association of eIF4E with other 
translation initiation factors by pull-down on m
7GDP–sepharose 
resin. The precipitation assay showed reduced association of 
eIF4G, eIF4A, and PABP with eIF4E, whereas the amount of 
eIF4E–BP1 in the precipitate was increased in R
− MEFs (Fig. 
6 B, top). The IGF-1R inhibitor induced similar alterations of 
translation initiation factors and impaired the formation of the 
translation initiation complex in SK-hep1 cells (Fig. S4 D). 
Together, these results suggest an important role for IGF-1R 
signaling in the regulation of translation initiation processes.
Cellular mRNAs differ hugely in the amount of eIF4F re-
quired for effi  cient translation (Gray and Wickens, 1998; Raught 
et al., 2000; Dever, 2002). Alterations of the general translational 
apparatus may preferentially affect the translation of weak mRNAs 
with extensive secondary structure in their 5′ UTR (Gray and 
Wickens, 1998; Raught et al., 2000; Dever, 2002; Rajasekhar 
et al., 2003; Moerke et al., 2007). We next investigated whether 
Figure 5.  Reduced translational synthesis of p53 in R
− MEFs. (A) Measure-
ment of p53 mRNA levels in MEFs by Northern blot analysis. p53 mRNA levels 
were detected by Northern blot analysis in R
+ and R
− MEFs. gapdh levels were 
shown as loading controls. (B) Reduced translation of p53 mRNA in R
− MEFs. 
p53 protein was immunoprecipitated from R
+ and R
− MEFs labeled with 
[
35S]methionine/cysteine and analyzed as described in Fig. 4 D (top, lanes 
3 and 4). An SDS-PAGE gel conﬁ  rmed equal loading of total cellular proteins.
Figure 6.  IGF-1R inhibition disrupts translation initiation complex formation. 
(A) Total protein synthesis rate is reduced in R
− MEFs. Pulse-labeled R
+ and R
− 
MEFs were lysed and analyzed by 20% trichloroacetic acid precipitation 
as described in Materials and methods. The incorporation of [
35S]methionine/
cysteine was measured by using a liquid scintillation counter. 
35S incorporation 
for R
+ MEFs was set to 100% in the set of comparisons. Values are mean ± 
SD from three experiments. *, P < 0.05. (B) Impaired assembly of the eIF4F 
complex in R
− MEFs. Cell extracts from R
+ and R
− MEFs were prepared in 
NLB buffer (see Materials and methods), followed by incubation with m
7GTP 
Sepharose 4B. Proteins eluted from Sepharose 4B were analyzed by Western 
blot analysis (top). Whole cell lysates were also subjected to Western blot 
analysis to determine the overall levels of proteins (bottom). JCB • VOLUME 178 • NUMBER 6 • 2007  1002
the modulations of the basal translational machinery by IGF-1R 
inhibition could evoke a selective translational effect. To this 
end, we examined the translation levels of several proteins with 
short half-lives upon IGF-1R inhibition because the levels of 
short-lived proteins are believed to be more sensitive to transla-
tional inhibition (Beuvink et al., 2005). We observed no change 
in the translation levels of short-lived proteins after IGF-1R 
inhibition, including p27 and c-fos (Fig. 7 A, bottom panels). 
These results indicate that the translational depression in re-
sponse to IGF-1R inhibition might be caused by an mRNA-
specifi  c mechanism.
Although it is likely that the attenuated translation initia-
tion induced by the impaired eIF4F system contributes to de-
creased p53 and mdm2 mRNA translation in response to IGF-1R 
inhibition, there might be additional mechanisms, including the 
regulation of translation elongation or termination on mRNA, 
for the observed effects of IGF-1R inhibition on p53 and mdm2 
mRNA translation. We examined the impact of eIF4F complex 
disruption on translation using a dicistronic mRNA construct that 
contains the FLAG-tagged p53, Mdm2, or c-fos coding region 
fl  anked by the corresponding 5′ and 3′ UTRs and a GFP coding 
sequence (Fig. 7 C, left). The respective coding region was trans-
lated in a cap-dependent manner, whereas the translation of the 
gfp sequence is driven by the cricket paralysis virus (CrPV) inter-
nal ribosome entry site (IRES), which is independent of transla-
tion initiation factors (Pestova and Hellen, 2003). We found that 
the expression of p53 and Mdm2 was down-regulated by AG1024 
treatment, whereas the levels of c-fos were unaltered (Fig. 7 C, 
right). The cytomegalovirus (CMV) promoter in the constructs 
drove similar levels of gfp mRNA expression under all condi-
tions (Fig. 7 C, right), thus excluding the possibility that there are 
differences in the promoter activity or transfection effi  ciency in 
AG1024-treated and -untreated cells. Importantly, GFP protein 
levels were unaltered after IGF-1R inhibition (Fig. 7 C, right), 
indicating that the initiation factor–independent translation is not 
inhibited. Interestingly GFP expression driven by the control 
vector (pIRES-GFP) was higher than that driven by other con-
structs, presumably because of the interference of the insert se-
quence (Fig. 7 C, right). Together, these fi  ndings suggest that 
translational control of p53 and Mdm2 expression by IGF-1R 
signaling is regulated at the level of initiation.
Modulation of p53 and mdm2 mRNA 
translation through 5′ UTRs
Weak mRNAs are subjected to gene-specifi  c regulation under 
conditions that reduce the effi  ciency of translation initiation 
owing to the presence of long, highly structured 5′ UTRs (Gray 
and Wickens, 1998; Raught et al., 2000; Dever, 2002). We there-
fore predicted the secondary structures of the 5′ UTRs of p53, 
mdm2, and c-fos mRNA using the program MFOLD (http://
frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-form1.cgi; 
Zuker, 2003). Consistent with the idea that the weak mRNA has 
a highly structured 5′ UTR, the sequences of the p53 and mdm2 
5′ UTR but not the c-fos 5′ UTR were predicted to form several 
highly structured stem loops (unpublished data).
To determine whether the UTRs of p53 or mdm2 mRNA 
are suffi  cient on their own to mediate IGF-1R signaling–
dependent translational regulation, we generated a series of con-
structs that contain a reporter sequence encoding fi  refl  y luciferase 
fl  anked by the UTRs of p53, mdm2, or c-fos mRNA (Fig. 7 B) and 
then transfected the constructs into SK-hep1 cells. We found 
that in the absence of the fl  anking UTRs or the presence of c-fos 
UTRs, AG1024 does not inhibit the translation of the reporter 
mRNA (Fig. 7 D). In contrast, the translatability of reporter 
mRNA containing p53 or mdm2 UTRs was decreased by 
AG1024 treatment (Fig. 7 D).
Because the mechanisms by which the 5′ and 3′ UTRs 
confer translational control of specifi  c mRNAs may be different 
(Wilkie et al., 2003), we examined the impact of the 5′ and 3′ 
UTRs of p53 and mdm2 mRNA on translational effi  ciency us-
ing chimeric luciferase reporter constructs (Fig. 7 B). We found 
that the three reporter mRNAs (p53–CUTR–luc, Mdm2–
CUTR–luc, and c-fos–CUTR–luc) lacking their respective 
5′ UTRs were less translated (Fig. 7 E). Nonetheless, AG1024 
inhibited the reporter mRNA translation in the presence of p53 
or mdm2 5′ UTR but not in the presence of their respective 
3′ UTRs (Fig. 7 E). In contrast, IGF-1R inhibition did not infl  uence 
the luciferase activity of the reporter construct c-fos–NUTR–luc 
and c-fos–CUTR–luc (Fig. 7 E). Moreover, the IGF-1R inhibitor 
attenuated the translatability of hybrid reporter mRNA contain-
ing p53 or mdm2 5′ UTR and c-fos 3′ UTR (Fig. 7 E), further 
demonstrating that the translational control of p53 and mdm2 
by IGF-1R inhibition is mediated by the respective 5′ UTR. 
Collectively, these data indicate that the 5′ UTR of p53 or mdm2 
mRNA is suffi  cient to enable the IGF-1R signaling-dependent 
control of protein translation.
The PI-3K–Akt–mTOR (molecular target of rapamycin) 
pathway has been demonstrated to regulate general protein syn-
thesis and translation of selected mRNAs (Gingras et al., 2001; 
Levine et al., 2006). We found that inhibition of PI-3K by 
LY294002, or mTOR by rapamycin, had no effect on p53 and 
Mdm2 expression (Fig. S5 A, available at http://www.jcb.org/
cgi/content/full/jcb.200703044/DC1), which suggests an mTOR-
independent mechanism for IGF-1R–mediated mRNA- specifi  c 
translational regulation. Extracellular signal-regulated kinase 
(ERK) signaling has also been shown to promote translation 
by facilitating assembly of the translation initiation complex 
(Kelleher et al., 2004). PD98059, a specifi  c inhibitor of MAPK 
and ERK kinase, did not alter the amount of p53 and Mdm2 
(Fig. S5 A). Furthermore, treatment of cells with LY294002 
(rapamycin) or PD98059 did not affect luciferase activity driven 
by p53–UTR–luc or Mdm2–UTR–luc (Fig. S5 C). It therefore 
appeared that the PI-3K–Akt–mTOR and ERK pathway, although 
inactivated after IGF-1R inhibition, may not be involved in re-
ducing p53 and mdm2 translation. It has been suggested that 
active glycogen synthase kinase (GSK)-3β phosphorylates and 
inhibits the translation initiation factor eIF2B (Welsh et al., 
1998). Because IGF-1 signaling inactivates GSK-3β and pro-
motes protein synthesis (Quevedo et al., 2000), we examined 
whether inhibition of IGF-1R activity could reduce p53 and 
mdm2 translation through activation of GSK-3β. The reduction 
of Mdm2 levels in AG1024-treated SK-hep1 cells was not in-
hibited by GSK-3β inhibitors SB216763 or SB415286, which 
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inhibitors had no effect on the luciferase activity of the chimeric 
reporter constructs (Fig. S5 D), further indicating that GSK-3β 
plays no part in the translational inhibition of p53 and Mdm2 by 
IGF-1R inactivation.
Discussion
Opposing effects of IGF-1R signaling on p53
Although p53 is frequently mutated in >50% of human cancers 
(Hainaut et al., 1997), a large fraction of cancers express wild-
type p53, which may be regulated by other mechanisms such as 
amplifi  cation of Mdm2 (Oliner et al., 1992) or deregulation of 
growth-factor signaling (Brown and Benchimol, 2005; Levine 
et al., 2006). In this study, we demonstrate that inactivation of 
IGF-1R signaling impairs p53 accumulation after DNA damage 
through translational modulation of the p53–Mdm2 feedback 
loop. On the one hand, the translation of both p53 and mdm2 
mRNA is attenuated upon IGF-1R inhibition. On the other 
hand, p53 protein becomes stabilized in response to IGF-1R 
inhibition because of reduced Mdm2 protein levels and is thus 
Figure 7. The  5′ UTR of p53 and mdm2 tran-
script mediates IGF-1R–dependent regulation 
of p53 and Mdm2 translation. (A) AG1024 
speciﬁ  cally reduces translational levels of p53. 
[
35S]methionine/cysteine pulse-labeled p27, 
c-fos, and p53 were immunoprecipitated from 
SK-hep1 cells treated with or without AG1024 
and analyzed by PhosphorImaging (bottom). 
Expression levels of p27, c-fos, and p53 pro-
teins were monitored by immunoblotting (top). 
Adjustment of brightness and contrast (
35S-p27 
panel) was performed with Photoshop 8.0 soft-
ware. (B) Chimeric UTR-luc constructs carrying 
the 5′ and/or 3′ UTR of p53, mdm2, and c-fos 
mRNA. Each construct is labeled with the cor-
responding number at the right side. (C) AG1024 
inhibits p53 and Mdm2 translation at the level 
of translation initiation; a schematic presentation 
of the FLAG-p53, FLAG-Mdm2, and FLAG–c-fos 
constructs containing the corresponding UTRs, 
CrPV IRES, and EGFP (left). SK-hep1 cells were 
transfected with the indicated expression vectors. 
Cells were treated with or without AG1024 
and analyzed for protein expression by immuno-
blotting with antibodies against FLAG and 
GFP. gfp mRNA levels were determined by 
semiquantitative RT-PCR. (D and E) 5′ UTRs of 
the p53 and mdm2 transcript impose IGF-1R 
signaling–mediated translational regulation. 
SK-hep1 cells were transiently cotransfected 
with the chimeric UTR-luc constructs and pRL–
SV40–renilla as described in Material and 
methods. After AG1024 treatment, luciferase 
activity was measured. Relative luciferase ac-
tivity is expressed as light units normalized for 
renilla luciferase activity. Data are presented as 
mean ± SD of three independent experiments 
performed in quadruplicate. Levels of lucifer-
ase transcripts were revealed by semiquantita-
tive RT-PCR. The number at the bottom of the 
panel is representative of the corresponding 
chimeric construct shown in B.JCB • VOLUME 178 • NUMBER 6 • 2007  1004
insensitive to further up-regulation of protein stability. IGF-1R 
inhibition therefore acts on p53 through two competing path-
ways (decreasing p53 protein synthesis and increasing p53 pro-
tein stability).
It is conceivable that p53 protein levels are determined by 
a balance between the opposing effects of IGF-1R signaling. In 
different cell types, the balance of the two competing pathways 
is likely to be different. Consistent with this idea, a lack of IGF-
1R activity led to reduced p53 protein levels in MEFs (Fig. 2 D), 
whereas in HCT116 and SK-hep1 cells there was no detectable 
difference in p53 expression levels upon IGF-1R inhibition 
(Figs. 4 B and 7 A). Moreover, in MCF-7 cells the IGF-1R in-
hibitor up-regulated p53 protein levels with reduced p53 and 
mdm2 mRNA translation (unpublished data), further support-
ing the notion that the opposing effects of IGF-1R signaling on 
p53 are dependent on cell type.
Previous papers showing that activation of IGF-1R signal-
ing decreases p53 expression in many systems are not contradic-
tory to our fi  ndings of translational regulation of p53 by IGF-1R 
signaling, as these papers do not reveal whether IGF-1R signal-
ing could regulate p53 mRNA translation (Leri et al., 1999; 
Héron-Milhavet and LeRoith, 2002; Jackson et al., 2006). In 
fact, our results indicate that a reduction in p53 mRNA transla-
tion by itself induced by IGF-1R inhibition may not always refl  ect 
and/or translate into a decline in p53 expression. Furthermore, 
IGF-1 signaling has been reported to be able to up-regulate p53 
expression (Wang et al., 1998). Thus, it is possible that the down-
regulation of p53 expression upon IGF-1R activation that was 
observed in previous studies is cell-context dependent and addi-
tionally might be associated with an increase in p53 translation. 
Our results also provide a possible explanation for previous ob-
servations that Mdm2 expression is up-regulated by IGF-1 sig-
naling (Leri et al., 1999; Héron-Milhavet and LeRoith, 2002).
Mechanisms of translational regulation 
of p53 and Mdm2 by IGF-1R
There are two general forms of translational control: mRNA-
specifi  c regulation and global control of protein synthesis (Gray 
and Wickens, 1998; Raught et al., 2000; Dever, 2002). Impor-
tantly, these two forms of regulation are not mutually exclusive 
(Gray and Wickens, 1998). We found that despite a reduction in 
global translation, the effect of IGF-1R inhibition on p53 and 
mdm2 mRNA translation is mRNA specifi  c because the 5′ UTR 
of p53 and mdm2 mRNA rather than the 5′ UTR of c-fos mRNA 
imposed the translational regulation by IGF-1R signaling (Fig. 7, 
D and E), nor did we observe a change in c-fos and p27 mRNA 
translation after IGF-1R inhibition (Fig. 7 A). mRNA-specifi  c 
regulation is either acquired by alterations of the general transla-
tional machinery or conferred by specialized mRNA binding 
factors (Gray and Wickens, 1998; Raught et al., 2000; Dever, 
2002). Previous papers have documented a translational regula-
tion of p53 and Mdm2 expression through the interactions of 
mRNA binding factors with the corresponding mRNAs (Mazan-
Mamczarz et al., 2003; Trotta et al., 2003; Takagi et al., 2005). 
Our fi  ndings from this study suggest a different mechanism by 
which IGF-1R signaling regulates p53 and mdm2 mRNA trans-
lation. We showed that IGF-1R inhibition led to reduced eIF4G 
expression and decreased eIF4E–BP1 phosphorylation (Figs. 6 B 
and S4 D), both of which in turn attenuated the formation of the 
eIF4F complex and may impair cap-dependent translation initia-
tion. Consistently, repression of p53 and mdm2 mRNA trans-
lation by IGF-1R inhibition was at the level of initiation, not 
elongation or termination, because there was no decrease in CrPV 
IRES–driven EGFP translation (Fig. 7 B). However, although it 
is likely that these observed inhibition effects are at least in part 
mediated by impairing the activity of the eIF4F complex, there 
could be additional mechanisms for the attenuated translation of 
p53 and mdm2 mRNA upon IGF-1R inhibition.
Many growth regulators are encoded by weak mRNAs, 
translation of which is highly eIF4F dependent and more sensi-
tive to small perturbations in eIF4F complex formation (Gray 
and Wickens, 1998; Raught et al., 2000; Dever, 2002; Rajasekhar 
et al., 2003; Moerke et al., 2007). The mechanisms of gene-specifi  c 
translational regulation by IGF-1R signaling presented in this 
paper may therefore not be limited to regulation of p53 and 
Mdm2 but may rather be of general signifi  cance in translational 
regulation of gene expression. It will be interesting to determine 
how many genes could be regulated at the translational level by 
IGF-1R signaling and how many physiological effects of IGF-
1R signaling could occur through translational effects. Although 
in our studies we show that IGF-1R signaling regulates p53 and 
mdm2 translation independent of Ras and the PI-3K–Akt–mTOR 
pathway, we cannot exclude the possibility that these pathways 
may be involved in IGF-1R–dependent translational regulation 
of other weak mRNAs.
The role of IGF-1R in cell survival 
and cell death
Two well-documented hallmarks of cancer are deregulation 
of cell proliferation and evasion of apoptosis (Hanahan and 
Weinberg, 2000). IGF-1R not only transmits mitogenic growth 
signals but also governs survival pathways, both of which are 
conducive to increased tumor growth (Pollak et al., 2004; 
  Samani et al., 2007). However, IGF-1R signaling has also been 
proposed to be involved in inducing contradictory signals, in-
cluding proapoptotic signaling (Kooijman, 2006), on malig-
nancy in different environments (Baserga, 2000; Samani et al., 
2007), though how IGF-1R functions as a proapoptotic factor is 
unclear. The fi  ndings presented in this paper implicate IGF-1R 
as a proapoptotic factor by modulating the response of p53 to 
DNA damage.
Because p53 is involved in cellular responses to oxidative 
damage (Finkel and Holbrook, 2000), our fi  ndings provide an 
explanation for the increased resistance observed in Igf-1r
+/− 
mice when challenged with oxidants (Holzenberger et al., 2003). 
Our data is also consistent with the notion that growth signals 
have the potential to sensitize cells to apoptosis (Evan and 
Littlewood, 1998). IGF-1R has been shown to be involved in 
TNF-α–induced apoptosis (Niesler et al., 2000) and in a non-
apoptotic form of cell death (Sperandio et al., 2000), both of 
which seem not to depend on p53 function. Thus IGF-1R signal-
ing can participate in both p53-dependent and -independent cell 
death. Together, these results provide an interesting contrast to 
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cells to apoptosis induced by chemotherapeutic drugs (Samani 
et al., 2007). Yet as shown in our studies, IGF-1R inhibition not 
only impairs p53-dependent apoptosis but also inactivates the 
PI-3K–Akt and ERK pathways, which have been shown to be 
important for the antiapoptotic activity of IGF-1R signaling 
(Párrizas et al., 1997; Gooch et al., 1999; Peruzzi et al., 1999). 
Therefore, upon IGF-1R inhibition, it is the balance between 
attenuated p53-dependent apoptosis and inactivated survival 
pathways that determines whether a cell survives or dies in re-
sponse to stress. One might expect that the inclination of the 
balance would be dependent on cell type and the nature of apop-
totic stimuli. Consistent with this idea, the loss of IGF-1R sen-
sitized cells to doxorubicin- and Taxol-induced apoptosis (Fig. 
S2 B), although p53 induction was attenuated (Fig. S2 A).
Our fi  ndings may have important implications for the 
design of therapeutic protocols that involve the targeting of 
IGF-1R signaling. In tumors with functional p53, where p53 is 
critical for chemotherapeutic response (Johnstone et al., 2002), 
small molecular therapy targeting IGF-1R, when used together 
with chemotherapy, may lead to the attenuation of cytotoxicity 
of chemotherapeutic drugs. However, because IGF-1R is im-
portant for cancer cell growth and survival, such therapy be-
tween courses of chemotherapy may well be useful (LeRoith 
and Helman, 2004).
In summary, we have shown that inactivation of IGF-1R 
leads to a specifi  c inhibition of p53 and mdm2 mRNA transla-
tion. Studies of the expression of chimeric constructs demon-
strate an essential role of the 5′ UTR of p53 and mdm2 mRNA 
in the translational regulation by IGF-1R inhibition. IGF-1R 
signaling therefore regulates p53 through competing pathways 
that involve decreasing p53 translation and enhancing p53 
protein stability, which lead to impaired p53 induction in re-
sponse to DNA damage. This may have important implications 
in cancer therapy.
Materials and methods
Cell culture and chemicals
R
− MEFs lacking Igf-1r have been described previously (Miura et al., 
1995). R
+ MEFs were obtained from R
− MEFs stably transfected with a 
plasmid containing human IGF-1R cDNA. Both cell lines were provided by 
R. Baserga (Thomas Jefferson University, Philadelphia, PA) and cultured in 
DME medium supplemented with 10% FBS (Invitrogen). SK-hep1, HCT116 
p53
+/+, and p53
–/– cells (provided by B. Vogelstein, Johns Hopkins Univer-
sity, Baltimore, MD) were maintained in standard medium.
AG1024, LY294002, PD98059, rapamycin, etoposide, doxorubicin, 
Taxol, and cycloheximide (CHX) were obtained from Calbiochem. 
SB216761, SB415286, and ionomycin were obtained from Sigma-
  Aldrich. 7-methyl GTP (m
7GTP) and m
7GTP-Sepharose 4B were obtained 
from GE Healthcare.
Constructs and transfections
Full lengths of IGF-1R-WT and IGF-1R-YF were isolated from pBPV–IGF-1R-
WT and pBPV–IGF-1R-YF (provided by R. Baserga) and subcloned into 
pCMV-Tag2B vector (Stratagene). p53DD lacking the transactivation and 
DNA-binding domain (amino acids 15–301) was derived from mouse 
cDNA by PCR and inserted downstream of GFP in a pEGFP-C1 vector 
(CLONTECH Laboratories, Inc.). p53bs-luc and p53ms-luc were provided 
by S.E. Kern (Johns Hopkins University). A 194-unit long oligonucleotide 
corresponding to the sequence of CrPV IRES was synthesized chemically 
and inserted upstream of GFP in the pEGFP-N3 vector (CLONTECH Labo-
ratories, Inc.) and named pIRES-GFP. The full length of p53, mdm2, or c-fos 
cDNA that contains 2,629, 2,357, and 2,084 nucleotides, respectively, 
was ampliﬁ  ed from human cDNA by PCR and cloned into the pIRES-GFP 
vector with a FLAG tag attached to the C terminus of the corresponding 
coding region under the CMV promoter. The UTRs of p53, mdm2, or c-fos 
were subcloned from the corresponding cDNA into the pCMV-luc vector 
containing a CMV-driven luciferase sequence.
For determination of the sub-G1 population, 10
6 MEFs were trans-
fected with 8 μg of the indicated plasmids and combined with or without 
1 μg cDNA coding for GFP. Transfections were performed using a transfection 
system (Nucleofector; Amaxa) according to the manufacturer’s instructions. 
70% transfection efﬁ  ciency of cells was obtained using solutions and pro-
grams recommended by the manufacturer. For reporter assay, cells were 
transfected with the indicated reporter plasmids by jetPEI transfection re-
agent (Polyplus). The empty pCMV-Tag2B vector was added to adjust total 
DNA amount to 1 μg per well.
Western blot and immunoprecipitation
After electrophoresis and transfer of samples onto Immobilon membrane 
(Millipore), the blots were probed with the following antibodies: anti-Mdm2 
(SMP14; Santa Cruz Biotechnology, Inc.; 2A10; Oncogene Research 
Products); anti–caspase-3, anti-PARP, anti–α-catenin, and anti-eIF4E (BD 
Bio  sciences); anti–eIF4E–BP1, anti-PABP, anti-pERK (T202/Y204), anti–
p-p70 S6k (T389), anti-p70 S6k, anti-akt, anti–p–IGF-1R (Y1131), and 
anti-p27 (Cell Signaling Technology); anti-p53 (FL-393), anti–c-fos (H-125), 
anti–IGF-1R (C-20), anti–p-akt (Ser473), anti-ubiquitin (FL-76), anti-GFP 
(FL), and anti-actin (I-19; Santa Cruz Biotechnology, Inc.); anti-FLAG 
(Sigma-Aldrich); anti-eIF4A (provided by H. Trachsel, University of Bern, 
Bern, Switzerland); anti-eIF4G (provided by S. Morley, University of Sus-
sex, Brighton, UK). The membranes were exposed to x-ray ﬁ  lm (Kodak), 
which was scanned (Scanjet 3570c; Hewlett-Packard) using software 
(Photo and Imaging 2.0; Hewlitt-Packard). The analysis of the images was 
performed with imaging software (Photoshop 8.0; Adobe).
Cell-death assays
Cell death was determined according to the percentage of sub-G1 DNA 
content by ﬂ  ow cytometry. For untransfected cells, cells were collected and 
ﬁ  xed with 70% cold ethanol overnight at −20°C. In transfected cells, after 
drug treatments for the indicated times, transfectants were collected and re-
suspended in 1% paraformaldehyde at room temperature for 10 min, cen-
trifuged, and ﬁ  xed in 70% cold ethanol at –20°C overnight. Fixed cells 
were then incubated in PBS containing 50 μg ml
−1 RNase A (Sigma-Aldrich) 
for 1 h at 37°C, followed by 30 μM propidium iodide (Sigma-Aldrich) 
staining. In each assay, either 10,000 (untransfected) or 50,000 (transfected) 
cells were collected by FACScan (BD Biosciences) and analyzed with software 
(WinMDI version 2.8; provided by J. Trotter, Scripps Research Institute, 
La Jolla, CA).
Reporter assays
Cells cotransfected with the indicated constructs and the PRL-SV40 vectors 
were harvested in lysis buffer and analyzed using a luciferase assay re-
agent according to the manufacturer’s instructions (Dual-Luciferase reporter 
assay system; Promega). The reporter activity was expressed as arbitrary 
luciferase units (ﬁ  reﬂ  y/renilla).
Northern blot analysis and semiquantitative RT-PCR
RNA was isolated using TRIzol (Invitrogen) and subjected to Northern blot 
analysis with indicated probes. Primers used were as follows: human p53 
(5′-T  C  C  T  A  C  A  C  C  G  G  C  G  G  C  C  C  C  T  G  C  A  C  -3′ and 5′-G  C  G  G  A  G  A  T  T  C  T  C  T  T  C-
C  T  C  T  G  T  G  -3′) and mouse p53 (5′-T  G  C  C  C  C  A  G  G  A  T  G  T  T  G  A  G  G  A  G  T  T  T  T  -3′ 
and 5′-CCCCCC A  T  G  C  A  G  G  A  G  C  T  A  T  T  A  C  A  C  A  -3′). The Northern blot 
hybridization bands were scanned into the computer using a scanner 
(PhosphorImager SI; Molecular Dynamics) and analyzed using software 
(ImageQuant; GE Healthcare).
cDNA was synthesized from total RNAs with the SuperScript pre-
ampliﬁ  cation system (Invitrogen). Primers used for semiquantitative RT-PCR 
analysis were as follows: for mdm2 mRNA, a 5′ (5′-C  G  C  C  C  C  G  T  G  A  A  G  -
G  A  A  A  C  -3′) and 3′ primer (5′-C  A  G  C  A  C  C  A  T  C  A  G  T  A  G  G  T  A  C  A  G  A  C  A  T  -3′); 
for gfp mRNA, a 5′ (5′-C  C  C  G  C  G  C  C  G  A  G  G  T  G  A  A  G  T  -3′) and 3′ primer 
(5′-C  G  T  C  G  C  C  G  A  T  G   GGGGTGTT-3′); for luciferase mRNA, a 5′ (5′-G  G  C-
G  C  G  G  T  C  G  G  T  A  A  A   GTTGTT-3′) and 3′ primer (5′-A  G  C  G  G  G  A  G  C  C  A  C  C  T-
G  A  T  A  G  C  -3′). The images of agarose gels were captured using the G:Box 
system (Syngene) and analyzed using software (Genesnap; Syngene).
Metabolic labeling and quantitative analysis of protein synthesis
For [
35S]methionine/cysteine label analysis, cells were incubated in methi-
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FBS (Invitrogen) for 1 h. 0.3 mCi [
35S]methionine/cysteine (GE Healthcare) 
was next added in 0.5 ml of free medium for 30 min. Lysates were prepared 
for the immunoprecipitation assay. Immunoprecipitated proteins were re-
solved by SDS-PAGE and visualized by PhosphorImaging. For quantitative 
analysis of total protein synthesis, lysates were prepared by standard proto-
cols and the incorporation of 
35S incorporation for cells was measured by 
using a liquid scintillation counter (LS 6500; Beckman Coulter).
For [
35S]methionine/cysteine pulse-label analysis cells were starved for 
methionine/cysteine for 1 h, and then pulse labeled with 0.75 mCi 
[
35S]methionine/cysteine for 1 h and chased for the indicated times with un-
labeled methionine/cysteine (1 mg ml
−1) added. The 
35S-labeled p53 or Mdm2 
in the immunoprecipitates from each time point was resolved and quantiﬁ  ed 
by PhosphorImaging and normalized to that of the zero time point.
Analysis of eIF4E-binding proteins
The m
7GTP pull-down assay was performed as described previously (Walsh 
and Mohr, 2004). In brief, after washing with cold PBS, 2 × 10
6 cells were 
lysed in 1 ml NLB (50 mM Hepes, pH 7.4, 150 mM NaCl, 2 mM EDTA, 
2 mM Na3VO4, protease inhibitor cocktail, and 0.5% NP-40) and then extracts 
were clariﬁ  ed by centrifugation at 10,000 g (4°C for 10 min). Supernatants 
were then incubated with 1 ml NLB including m
7GTP-Sepharose 4B (60 μl of 
50/50 slurry) at 4°C for 1 h. The beads were centrifuged at 2500 g, and 
then washed with NLB. The m
7GTP-agarose was resuspended in 100 μl NLB 
containing 100 μM m
7GTP at 4°C for 30 min. The elute was collected and 
diluted with an equal volume of 2× SDS sample buffer and boiled. The eIF4E-
bound proteins were analyzed by SDS-PAGE and immunoblotting.
Online supplemental material
Fig. S1 presents the expression analysis of p53 and p21 and the apoptosis 
analysis of R
+ and R
− MEFs upon doxorubicin or Taxol treatment and the 
cell cycle distribution of R
+ and R
− MEFs after etoposide treatment. Fig. S2 
shows that inhibition of IGF-1R attenuates etoposide-induced p53 accumula-
tion and apoptosis in tumor cells and has no effect on ionomycin-induced 
p53-independent apoptosis. Fig. S3 shows that inactivation of IGF-1R leads 
to enhanced p53 protein stability in tumor cells. Fig. S4 shows that inhibi-
tion of IGF-1R activity results in a reduced p53 translation. Fig. S5 shows 
that IGF-1R inhibition impairs p53 and Mdm2 translation through an ERK- 
and GSK-3β–independent and probably PI-3K–Akt–mTOR–independent 
mechanism. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200703044/DC1.
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